# PET Imaging With Cu-64 Labeled Trastuzumab in HER2+ Metastatic Breast Cancer

> **NCT00605397** · PHASE1 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 11 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **RADIATION:** PET Imaging With Cu-64 Labeled Trastuzumab
- **RADIATION:** PET Imaging With Cu-64 Labeled Trastuzumab

## Key facts

- **NCT ID:** NCT00605397
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** 2013-12
- **Final completion:** 2013-12
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2015-12-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00605397

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00605397, "PET Imaging With Cu-64 Labeled Trastuzumab in HER2+ Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00605397. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*